1. Stakeholders' perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases

   Kosse, L. J., Jessurun, N. T., Vonkeman, H. E., Tas, S. W., Nurmohamed, M. T., Hoentjen, F., van Doorn, M. B. A., van Puijenbroek, E. P., van den Bemt, B. J. F. & de Vries, M., 30-Jul-2020, In : Expert Opinion on Drug Safety.

   Research output: Contribution to journal › Article › Academic › peer-review

2. Immune-mediated inflammatory disease patients' preferences in adverse drug reaction information regarding biologics

   Kosse, L. J., Weits, G., Vonkeman, H. E., Spuls, P. I., Van Den Bemt, B. J. F., Tas, S. W., Hoentjen, F., Nurmohamed, M. T., Van Doorn, M. B. A., Van Puijenbroek, E. P. & Jessurun, N. T., 7-Jul-2020, In : Expert Opinion on Drug Safety. p. 1-5 5 p.

   Research output: Contribution to journal › Article › Academic › peer-review

3. Safety profile of non-vitamin K oral anticoagulants (NOACs) from a patient perspective: A web-based cohort event monitoring study

   Rolfes, L., Ekhart, C., Hendriks, J., van der Horst, P. & van Puijenbroek, E., 2019, In : Expert Opinion on Drug Safety. 18, 9, p. 869-874 6 p.

   Research output: Contribution to journal › Article › Academic › peer-review

4. First experiences with a tool to measure the level of clinical information present in adverse drug reaction reports

   Oosterhuis, I., Rolfes, L., Ekhart, C., Muller-Hansma, A. & Harmark, L., 2018, In : Expert Opinion on Drug Safety. 17, 2, p. 111-115 5 p.

   Research output: Contribution to journal › Article › Academic › peer-review

5. An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder

   Groenman, A. P., Schweren, L. J. S., Dietrich, A. & Hoekstra, P. J., Apr-2017, In : Expert Opinion on Drug Safety. 16, 4, p. 455-464 10 p.

   Research output: Contribution to journal › Review article › Academic › peer-review

View all (16) »